Fundraising Fox

Rallybio, LLC

NASDAQ: RLYB

New Haven, US · 6 known investors

rallybio.com ↗

Rallybio is a biopharmaceutical company developing therapies for rare diseases, with a pipeline focused on complement dysregulation and hematology. Its assets include RLYB116, a C5 inhibitor aimed at complement-mediated diseases.

BiotechHealthtech

Founders & leadership

SUSteve Uden
Steve UdenCo-Founder and CEO

Investors · 6

5AM VenturesBoston · $100K – $4M
Canaan PartnersStamford · $500K – $20M
Connecticut InnovationsNew Haven · $500K – $2M
F-Prime Capital PartnersCambridge · $3M – $10M
Mitsui Global InvestmentMenlo Park · $500K – $10M
Solasta VenturesBoston

Competitors · 1

by search overlap
Bridgebio23 shared keywordsBridgeBio is a biopharmaceutical company that develops medicines for genetic diseases and cancers driven by specific genetic mutations, with a pipeline spanning conditions such as transthyretin amyloidosis, limb-girdle muscular dystrophy, achondroplasia, and hypoparathyroidism. Its programs range from preclinical stages through to approved therapies.

Companies competing with Rallybio, LLC for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Rallybio, LLC do?
Rallybio is a biopharmaceutical company developing therapies for rare diseases, with a pipeline focused on complement dysregulation and hematology. Its assets include RLYB116, a C5 inhibitor aimed at complement-mediated diseases.
Who founded Rallybio, LLC?
Rallybio, LLC was founded by Steve Uden.
Who are Rallybio, LLC's investors?
Rallybio, LLC's investors include 5AM Ventures, Canaan Partners, Connecticut Innovations, F-Prime Capital Partners, Mitsui Global Investment, Solasta Ventures.
Where is Rallybio, LLC headquartered?
Rallybio, LLC is headquartered in New Haven, US.